MedTrace Logo

Effect of Continuous Intake of Ergothioneine-containing Supplements on Skin Condition

NCT06886061 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2025-03-20

No results posted yet for this study

Summary

This trial employed a non-randomized, double-blind, placebo-controlled design to evaluate the effects of DR. ERGO® Capsules (each containing 30mg of ergothioneine) on the skin condition of women aged 35 to 59 after continuous daily intake for 8 weeks. The trial assessed skin condition across multiple dimensions, including brightness, color tone, melanin, erythema, gloss, elasticity, and spots, using various instruments and questionnaire surveys. Additionally, safety was monitored through daily log records and safety evaluations.

Conditions

  • Skin

Interventions

DIETARY_SUPPLEMENT

The capsules contain Ergothioneine.

Take one 30 mg Ergothioneine capsule orally every day for a period of eight weeks.

DIETARY_SUPPLEMENT

The capsules do not contain Ergothioneine.

Take one capsule devoid of Ergothioneine orally every day for a period of eight weeks.

Sponsors & Collaborators

  • Shanghai EGT Synbio Group Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Kaneko Takeshi · Japan Clinical Trial Association

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
59 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-10-09
Primary Completion
2024-12-10
Completion
2025-03-03

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06886061 on ClinicalTrials.gov